AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013

  AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013

PR Newswire

REDWOOD CITY, Calif., Aug. 30, 2013

REDWOOD CITY, Calif., Aug. 30, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that Richard King, President and
CEO, will present a corporate overview at the Stifel Healthcare Conference
2013 at the Four Seasons Hotel in Boston, MA. The presentation is scheduled
for Wednesday, September 11, 2013 at 9:45 a.m. ET/6:45 a.m. PT.

The presentation will be webcast live and can be accessed through the
Investors page at www.acelrx.com. For those not available to listen to the
live broadcast, a replay of the presentations will be archived for 90 days and
available through the Investors page on www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain. AcelRx's lead product candidate,
Zalviso, is designed to solve the problems associated with post-operative
intravenous patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine, the
invasive IV route of delivery and the complexity of infusion pumps. Zalviso
has successfully completed all three of its planned Phase 3 clinical trials
and a New Drug Application submission is planned for the third quarter of
2013. AcelRx has announced positive top-line results for a Phase 2 trial for
ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute
pain, funded through a grant from U.S. Army Medical Research and Materiel
Command. The company has two additional pain treatment product candidates,
ARX-02 and ARX-03, which have completed Phase 2 clinical development. For
additional information about AcelRx's clinical programs please visit
www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not
limited to, statements related to the process and timing of anticipated future
clinical development of AcelRx Pharmaceuticals' product candidates, the
potential submission of an NDA for Zalviso and the timing thereof, therapeutic
and commercial potential of Zalviso and the anticipated timing and therapeutic
and commercial potential of other AcelRx product candidates. These
forward-looking statements are based on AcelRx's current expectations and
inherently involve significant risks and uncertainties. AcelRx's actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to: the
success, cost and timing of AcelRx's product development activities and
clinical trials; any delays or inability to obtain, regulatory approval of its
product candidates; its ability to obtain adequate clinical supplies of the
drug and device components of its product candidates; its ability to attract
funding partners or collaborators with development, regulatory and
commercialization expertise; its ability to obtain sufficient financing to
complete development and registration of its product candidates in the United
States and Europe; its ability to obtain and maintain regulatory approvals of
its product candidates; the market potential for its product candidates; the
accuracy of AcelRx's estimates regarding expenses, capital requirements and
needs for financing; and other risks detailed in the "Risk Factors" and
elsewhere in AcelRx's U.S. Securities and Exchange Commission filings and
reports, including its Quarterly Report on Form 10-Q for the three months
ended June 30, 2013, filed August 12, 2013. AcelRx undertakes no duty or
obligation to update any forward-looking statements contained in this release
as a result of new information, future events or changes in its expectations.

(Logo:http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)

SOURCE AcelRx Pharmaceuticals, Inc.

Website: http://www.acelrx.com
Contact: Jim Welch, Chief Financial Officer, 650.216.3511, jwelch@acelrx.com